Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
This trial is active, not recruiting.
|Treatments||radiofrequency ablation, cytokine-induced killer cells|
|Sponsor||The First People's Hospital of Changzhou|
|Start date||July 2015|
|End date||June 2038|
|Trial size||50 participants|
|Trial identifier||NCT02487693, ovarian001|
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.
|Intervention model||parallel assignment|
time frame: 1 year
time frame: 4 weeks
Female participants from 30 years up to 70 years old.
Inclusion Criteria: 1. patients diagnosed with FIGO stage II ovarian carcinoma; 2. cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed; 3. medical records maintain comprehensive data on treatment and follow-up; 4. no history of previous malignancies. Exclusion Criteria: 1. neoadjuvant chemotherapy applied; 2. less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed; 3. medical records maintain incomplete data on treatment or follow-up; 4. history of previous malignancy.
|Description||The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with ovarian carcinoma.|
Call for more information